Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
ID: 337101Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/337101

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAS-22-096.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced the "Stimulating Hematology Investigation: New Endeavors (SHINE)" grant opportunity, aimed at fostering innovative research in nonmalignant hematology. This program invites investigator-initiated R01 grant applications focused on basic and early translational research in hematology, addressing critical areas such as blood cell development and the impact of aging on hematopoiesis. With an anticipated funding amount of approximately $2,150,000 for FY2022, the NIH plans to support 2-9 awards, with projects lasting up to five years. Interested applicants must adhere to strict submission guidelines and deadlines, with applications due by January 7, 2025. For further inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional information can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAS-22-096.html.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAS-22-096-Full-Announcement.html
    PAS-22-096.html
    The Department of Health and Human Services (HHS) has issued a funding opportunity titled "Stimulating Hematology Investigation: New Endeavors (SHINE)" aimed at promoting innovative research in nonmalignant hematology. The program, supported by the National Institutes of Health (NIH) through multiple institutes including the NIDDK, NIA, and NHLBI, invites R01 grant applications focused on basic and early translational hematology research. Emphasizing dynamic research topics that will evolve over time, SHINE aims to close knowledge gaps in areas such as blood cell development and the effects of aging on hematopoiesis. Applications are due at various cycles, with a total funding of approximately $2,150,000 anticipated for FY2022, supporting 2-9 awards. The scope of projects can extend up to five years, and applicants must follow strict submission guidelines, including prior registrations with necessary agencies. The competitive selection process emphasizes scientific merit and relevance to program priorities, with detailed evaluation criteria set forth for the review process. The document outlines requirements for eligibility, application instructions, review information, and administrative guidelines, aiming to foster high-impact research within the hematology community.
    Similar Opportunities
    Limited Competition: Physician Scientist Transition to Independence in Blood Science Research (R00 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Heart, Lung, and Blood Institute (NHLBI), has announced a Limited Competition Funding Opportunity titled "Physician Scientist Transition to Independence in Blood Science Research" (R00 - Clinical Trial Optional). This initiative aims to support the transition of outstanding blood science researchers with clinical doctorate degrees from mentored research positions to independent faculty roles, providing up to three years of funding for innovative research in blood science. The program is particularly focused on enhancing the scientific workforce by promoting diversity and fostering independent research careers that address critical health challenges in hematology. Interested applicants must submit their proposals by March 28, 2025, with a total funding ceiling of $250,000 available for new awards, and can direct inquiries to grantsinfo@nih.gov for further information.
    Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)." This initiative aims to support the development of innovative tools and technologies that address significant challenges in kidney, urologic, and hematologic research, encouraging high-risk, exploratory projects that differ from traditional R01 grants. The funding, with a maximum budget of $275,000 over two years, is open to a diverse range of eligible applicants, including various educational institutions and community organizations, with applications due by January 7, 2025. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-119.html.
    Investigator-Initiated Research in Genomics and Health Equity (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Investigator-Initiated Research in Genomics and Health Equity" (RFA-HG-23-017), aimed at promoting health equity through innovative genomic research. This initiative encourages applicants to propose research that enhances the understanding and application of genomics across diverse U.S. populations, with a particular focus on engaging underrepresented groups and incorporating a Plan for Enhancing Diverse Perspectives (PEDP). The NIH plans to commit significant funds, with a maximum budget of $500,000 in direct costs per year for projects lasting four to five years, and applications are due by July 8, 2025. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the full announcement at NIH Grants.
    Advancing Genomic Medicine Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Genomic Medicine Research (R21 Clinical Trial Optional)" aimed at stimulating innovative research in the integration of genomic information into clinical care, particularly for populations experiencing health disparities. This initiative encourages proposals that address implementation science, barriers to genomic medicine, and the integration of genomic data with health and social determinants, with a focus on enhancing health equity among underrepresented groups. The grant provides funding up to $250,000, with applications open from November 1, 2023, until the close date of February 11, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the NHLBI Early Phase Clinical Trials (R33), aimed at supporting investigator-initiated Phase I clinical trials for therapeutic and diagnostic interventions targeting heart, lung, blood, and sleep (HLBS) disorders. Applicants are required to be prepared to initiate their clinical trials within the first quarter of the project period and must demonstrate readiness in obtaining necessary regulatory approvals, including FDA and IRB, prior to the award. This funding is crucial for addressing unmet medical needs through innovative research, with a maximum budget of $1.515 million per year and a project duration of up to three years, contingent upon achieving specific milestones. Interested applicants should note the application deadline of June 4, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov for further details.
    Short-Term Research Education Program to Enhance Diversity in Health-Related Research (R25 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), is offering a federal grant opportunity titled "Short-Term Research Education Program to Enhance Diversity in Health-Related Research (R25 Clinical Trial Not Allowed)." This program aims to support educational activities that enhance the diversity of the biomedical, behavioral, and clinical research workforce by providing research experiences and related opportunities for individuals from underrepresented groups. The initiative is crucial for addressing health disparities in cardiovascular, pulmonary, and hematologic diseases by fostering a diverse scientific workforce. Interested applicants can apply for funding up to $175,000 per year for a maximum of five years, with applications opening on December 29, 2023, and a submission deadline of August 19, 2026. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-25-001.html.
    Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed)" aimed at stimulating innovation in the implementation and sharing of genomic information in clinical care across diverse populations. This initiative encourages applications for small research projects that explore the integration of genomic data into clinical practice, assess barriers to implementation, and develop innovative data analysis techniques, particularly focusing on underrepresented populations in genomic research. The maximum budget for each application is $50,000 over a two-year period, with a total funding expectation of approximately $150,000 for FY 2024. Interested applicants must submit their proposals by February 12, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Maximizing the Scientific Value of the NHLBI Biologic Biospecimen Repository: Scientific Opportunities for Exploratory Research (R21)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Maximizing the Scientific Value of the NHLBI Biologic Biospecimen Repository: Scientific Opportunities for Exploratory Research (R21)" to support exploratory research utilizing existing biospecimens relevant to heart, lung, and blood diseases. This grant aims to enhance the scientific utility of the NHLBI Biologic Specimen Repository by encouraging researchers to generate preliminary data that can inform future studies, with a focus on maximizing the value of stored collections. A total of $1,155,000 is anticipated for competitive awards from FY2023 through FY2025, with individual budgets capped at $75,000 for a maximum two-year project period. Interested applicants must submit their proposals by December 10, 2024, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional)" aimed at supporting small-scale research projects that enhance health equity through genomic research. The initiative seeks to develop innovative approaches and metrics to ensure the equitable application of genomics in improving health outcomes for U.S. populations, particularly focusing on historically underrepresented groups in biomedical research. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofit organizations, and state governments, with funding available up to $200,000 annually for a maximum of two years. Interested parties should submit their applications by July 8, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details at https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-23-018.html.
    Advancing Genomic Medicine Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Advancing Genomic Medicine Research (R01 Clinical Trial Optional)" aimed at enhancing the use and sharing of genomic information in clinical care across diverse populations. This initiative seeks proposals that focus on understanding the implementation of genomic medicine, addressing barriers to access, and developing analytical tools for clinical genomic data, with a strong emphasis on inclusivity for populations experiencing health disparities. The NIH has allocated approximately $2.4 million for three projects, with an additional project funded by the National Cancer Institute, and applicants are required to submit a Plan for Enhancing Diverse Perspectives (PEDP) as part of their proposals. Interested parties must submit their applications by February 11, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.